Nexgard Spectra

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

afoxolaner, milbemiċin oxime

Available from:

Boehringer Ingelheim Vetmedica GmbH

ATC code:

QP54AB51

INN (International Name):

afoxolaner, milbemycin oxime

Therapeutic group:

Klieb

Therapeutic area:

Endectocides, prodotti kontra l-Parassiti, insettiċidi u sustanzi, milbemiċin oxime, kombinazzjonijiet

Therapeutic indications:

Għat-trattament tal-briegħed u l-qurdien jigdem fil-klieb meta l-prevenzjoni tal-mard tal-heartworm (Dirofilaria immitis larva), angiostrongylosis (tnaqqis fil-livell tal-adulti immaturi (L5) u adulti ta ' Angiostrogylus vasorum), thelaziosis (adulti Thelazia callipaeda) u/jew trattament ta gastro-nematodu infestazzjonijiet huwa indikat. It-trattament minn infestazzjonijiet tal-briegħed (Ctenocephalides felis u C. canis) fil-klieb għal 5 ġimgħat. It-trattament ta ' qurdien infestazzjonijiet (Dermacentor reticulatus, Ixodes ricinus, Ixodes hexagonus, Rhipicephalus sanguineus) fil-klieb, għal 4 ġimgħat. Il-briegħed u l-qurdien għandhom jingħaqdu ma 'l-ospitant u jibdew jgħumu sabiex ikunu esposti għas-sustanza attiva. It-trattament ta ' infestazzjonijiet bil-adulti gastrointestinali, nematodi tal-ispeċijiet li ġejjin: - imsaren (Toxocara canis u Toxascaris leonina), anċilostomi (Ancylostoma caninum, Ancylostoma braziliense u Ancylostoma ceylanicum) u ħniex (Trichuris vulpis). Trattament ta ' domodicosis (ikkawżata minn Demodex canis). Kura għal sarcoptic mange (ikkawżata minn Sarcoptes scabiei var. canis). Il-prevenzjoni tal-mard tal-heartworm (Dirofilaria immitis larva) b'amministrazzjoni kull xahar. Il-prevenzjoni ta angiostrongylosis (bit-tnaqqis tal-livell ta 'l-infezzjoni bil-adulti immaturi (L5) u l-adulti l-istadji ta' Angiostrogylus vasorum) b'amministrazzjoni kull xahar. Il-prevenzjoni ta'l-istabbiliment tal-thelaziosis (adulti Thelazia callipaeda eyeworm l-infezzjoni) b'amministrazzjoni kull xahar.

Product summary:

Revision: 9

Authorization status:

Awtorizzat

Authorization date:

2015-01-15

Patient Information leaflet

                                17
B. FULJETT TA’ TAGĦRIF
18
FULJETT TA’ TAGĦRIF :
NEXGARD SPECTRA 9 MG/ 2 MG PILLOLI LI JINTMAGĦDU GĦAL KLIEB 2−3.5
KG
NEXGARD SPECTRA 19 MG/ 4 MG PILLOLI LI JINTMAGĦDU GĦAL KLIEB
>3.5−7.5 KG
NEXGARD SPECTRA 38 MG/ 8 MG PILLOLI LI JINTMAGĦDU GĦAL KLIEB
>7.5−15 KG
NEXGARD SPECTRA 75 MG/ 15 MG PILLOLI LI JINTMAGĦDU GĦAL KLIEB
>15−30 KG
NEXGARD SPECTRA 150 MG/ 30 MG PILLOLI LI JINTMAGĦDU GĦAL KLIEB
>30−60 KG
1.
L-ISEM U L-INDIRIZZ TAD-DETENTUR TAL-AWTORIZZAZZJONI GĦAT-
TQEGĦID FIS-SUQ U TAD-DETENTUR TAL-AWTORIZZAZZJONI GĦALL-
MANIFATTURA RESPONSABBLI GĦALL-ĦRUĠ TAL-LOTT, JEKK DIFFERENTI
Detentur tal-awtorizzazzjoni għat-tqegħid fis-suq
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
IL-ĠERMANJA
Manifattur responsabbli għall-ħrug tal-lott:
Boehringer Ingelheim Animal Health France SCS,
4 Chemin du Calquet,
31000 Toulouse,
FRANCE
2.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
NEXGARD SPECTRA 9 mg/ 2 mg pilloli li jintmagħdu għal klieb 2−3.5
kg
NEXGARD SPECTRA 19 mg/ 4 mg pilloli li jintmagħdu għal klieb
>3.5−7.5 kg
NEXGARD SPECTRA 38 mg/ 8 mg pilloli li jintmagħdu għal klieb
>7.5−15 kg
NEXGARD SPECTRA 75 mg/ 15 mg pilloli li jintmagħdu għal klieb
>15−30 kg
NEXGARD SPECTRA 150 mg/ 30 mg pilloli li jintmagħdu għal klieb
>30−60 kg
Afoxolaner, milbemycin oxime
3.
DIKJARAZZJONI TAS-SUSTANZA(I) ATTIVA(I) U INGREDJENT(I) OĦRA
Kull pillola li tintmagħad fiha s-sustanzi attivi:
NEXGARD SPECTRA
Afoxolaner (mg)
Milbemycin oxime (mg)
pilloli li jintmagħdu għal klieb 2−3.5 kg
9.375
1.875
pilloli li jintmagħdu għal klieb > 3.5−7.5 kg
18.75
3.75
pilloli li jintmagħdu għal klieb > 7.5−15 kg
37.50
7.50
pilloli li jintmagħdu għal klieb > 15−30 kg
75.00
15.00
pilloli li jintmagħdu għal klieb > 30−60 kg
150.00
30.00
Pilloli ħomor sa kannella fl-aħmar bid-dbabar, b’forma tonda
(pilloli għal klieb 2−3.5 kg) jew b’forma
rettangolari (pilloli għal klieb > 3.5−7.5 kg, pilloli għal klieb
>7.5−15 kg, pilloli għal
klieb > 15−30 kg u pilloli g
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
KARATTERISTIĊI TAL-PRODOTT FIL-QOSOR
2
1.
ISEM TAL-PRODOTT MEDIĊINALI VETERINARJU
NEXGARD SPECTRA 9 mg/ 2 mg pilloli li jintmagħdu għal klieb 2−3.5
kg
NEXGARD SPECTRA 19 mg/ 4 mg pilloli li jintmagħdu għal klieb
>3.5−7.5 kg
NEXGARD SPECTRA 38 mg/ 8 mg pilloli li jintmagħdu għal klieb
>7.5−15 kg
NEXGARD SPECTRA 75 mg/ 15 mg pilloli li jintmagħdu għal klieb
>15−30 kg
NEXGARD SPECTRA 150 mg/ 30 mg pilloli li jintmagħdu għal klieb
>30−60 kg
2.
KOMPOŻIZZJONI KWALITATTIVA U KWANTITATTIVA
Kull pillola li tintmagħad fiha:
SUSTANZI ATTIVI:
NEXGARD SPECTRA
Afoxolaner (mg)
Milbemycin oxime (mg)
pilloli li jintmagħdu għal klieb 2−3.5 kg
9.375
1.875
pilloli li jintmagħdu għal klieb > 3.5−7.5 kg
18.75
3.75
pilloli li jintmagħdu għal klieb > 7.5−15 kg
37.50
7.50
pilloli li jintmagħdu għal klieb >15−30 kg
75.00
15.00
pilloli li jintmagħdu għal klieb > 30−60 kg
150.00
30.00
Għal-lista sħiħa tal-ingredjenti (mhux attivi), ara s-sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pilloli li jintmagħdu.
Pilloli ħomor sa kannella fl-aħmar bid-dbabar, b’forma tonda
(pilloli għal klieb 2−3.5 kg) jew
b’forma rettangolari (pilloli għal klieb >3.5−7.5 kg, pilloli
għal klieb >7.5−15 kg, pilloli għal
klieb >15−30 kg u pilloli għal klieb > 30−60 kg).
4.
TAGĦRIF KLINIKU
4.1
SPEĊI LI FUQHOM SER JINTUŻA L-PRODOTT
Klieb.
4.2
INDIKAZZJONIJIET GĦAL UŻU TAL-PRODOTT LI JISPEĊIFIKAW L-ISPEĊI LI
FUQHOM SE JINTUŻA L-PRODOTT.
Kura ta’ infestazzjonijiet bi briegħed u qurdien fil-klieb meta
l-prevenzjoni fl-istess waqt ta’
heartworm disease (larvae tad-
_Dirofilaria immitis_
), angiostrongylosis (tnaqqis fil-livell ta’ adulti
immaturi (L5) u adulti ta’
_Angiostrongylus vasorum_
),thelaiosis (adulta tat-
_Thelazia callipaeda_
) u/jew
il-kura ta’ infestazzjonijiet gastrointestinali bin-nematodi hija
indikata.
Kura ta’ infestazzjonijiet bi briegħed (
_Ctenocephalides felis _
u
_C. canis)_
fil-klieb għal 5 ġimgħat.
Kura ta’ infestazzjonijiet bil-qurdien (
_Dermacento
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 14-12-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 14-12-2021
Public Assessment Report Public Assessment Report Bulgarian 15-10-2019
Patient Information leaflet Patient Information leaflet Spanish 14-12-2021
Public Assessment Report Public Assessment Report Spanish 15-10-2019
Patient Information leaflet Patient Information leaflet Czech 14-12-2021
Public Assessment Report Public Assessment Report Czech 15-10-2019
Patient Information leaflet Patient Information leaflet Danish 14-12-2021
Public Assessment Report Public Assessment Report Danish 15-10-2019
Patient Information leaflet Patient Information leaflet German 14-12-2021
Public Assessment Report Public Assessment Report German 15-10-2019
Patient Information leaflet Patient Information leaflet Estonian 14-12-2021
Public Assessment Report Public Assessment Report Estonian 15-10-2019
Patient Information leaflet Patient Information leaflet Greek 14-12-2021
Public Assessment Report Public Assessment Report Greek 15-10-2019
Patient Information leaflet Patient Information leaflet English 14-12-2021
Public Assessment Report Public Assessment Report English 15-10-2019
Patient Information leaflet Patient Information leaflet French 14-12-2021
Public Assessment Report Public Assessment Report French 15-10-2019
Patient Information leaflet Patient Information leaflet Italian 14-12-2021
Public Assessment Report Public Assessment Report Italian 15-10-2019
Patient Information leaflet Patient Information leaflet Latvian 14-12-2021
Public Assessment Report Public Assessment Report Latvian 15-10-2019
Patient Information leaflet Patient Information leaflet Lithuanian 14-12-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 14-12-2021
Public Assessment Report Public Assessment Report Lithuanian 15-10-2019
Patient Information leaflet Patient Information leaflet Hungarian 14-12-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 14-12-2021
Public Assessment Report Public Assessment Report Hungarian 15-10-2019
Patient Information leaflet Patient Information leaflet Dutch 14-12-2021
Public Assessment Report Public Assessment Report Dutch 15-10-2019
Patient Information leaflet Patient Information leaflet Polish 14-12-2021
Public Assessment Report Public Assessment Report Polish 15-10-2019
Patient Information leaflet Patient Information leaflet Portuguese 14-12-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 14-12-2021
Public Assessment Report Public Assessment Report Portuguese 15-10-2019
Patient Information leaflet Patient Information leaflet Romanian 14-12-2021
Public Assessment Report Public Assessment Report Romanian 15-10-2019
Patient Information leaflet Patient Information leaflet Slovak 14-12-2021
Public Assessment Report Public Assessment Report Slovak 15-10-2019
Patient Information leaflet Patient Information leaflet Slovenian 14-12-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 14-12-2021
Public Assessment Report Public Assessment Report Slovenian 15-10-2019
Patient Information leaflet Patient Information leaflet Finnish 14-12-2021
Public Assessment Report Public Assessment Report Finnish 15-10-2019
Patient Information leaflet Patient Information leaflet Swedish 14-12-2021
Public Assessment Report Public Assessment Report Swedish 15-10-2019
Patient Information leaflet Patient Information leaflet Norwegian 14-12-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 14-12-2021
Patient Information leaflet Patient Information leaflet Icelandic 14-12-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 14-12-2021
Patient Information leaflet Patient Information leaflet Croatian 14-12-2021
Public Assessment Report Public Assessment Report Croatian 15-10-2019